FY2026 EPS Estimates for Novartis Raised by Erste Group Bank

Novartis AG (NYSE:NVS) – Equities researchers at Erste Group Bank boosted their FY2026 earnings per share estimates for Novartis in a research note issued on Tuesday, September 8th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $8.99 per share for the year, up from their prior forecast of $8.95. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The business had revenue of $14.95 billion during the quarter.

Several other research analysts have also weighed in on the company. HSBC raised Novartis from a “reduce” rating to a “hold” rating and upped their price target for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Royal Bank Of Canada initiated coverage on Novartis in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Citigroup restated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Novartis presently has a consensus rating of “Hold” and a consensus target price of $153.00.

Novartis Stock Down 0.3%

Shares of NYSE:NVS opened at $138.64 on Monday. The firm has a 50 day simple moving average of $153.49 and a 200 day simple moving average of $152.53. The company has a market cap of $264.55 billion, a PE ratio of 20.91, a price-to-earnings-growth ratio of 2.69 and a beta of 0.45. Novartis has a 52 week low of $121.57 and a 52 week high of $170.46. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Fisher Asset Management LLC boosted its holdings in Novartis by 3.1% in the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock worth $1,029,317,000 after purchasing an additional 226,484 shares in the last quarter. Bank of America Corp DE raised its holdings in Novartis by 9.1% during the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock valued at $758,067,000 after buying an additional 413,778 shares in the last quarter. Auto Owners Insurance Co lifted its holdings in Novartis by 13,687.0% in the 4th quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after purchasing an additional 4,594,726 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Novartis by 10.3% in the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock worth $617,562,000 after purchasing an additional 419,988 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in Novartis by 1.9% during the first quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock worth $347,649,000 after purchasing an additional 41,520 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.